Mohamed Shengir

Novel non-invasive markers for monitoring hepatic steatosis, liver fibrosis, and mortality risk in people with HCV and HIV: exploring the impact of antiviral therapy and metabolic transitions

Mohamed Shengir

Background. In the era of curative antivirals for hepatitis C virus (HCV) and potent antiretroviral therapy (ART) for human immunodeficiency virus (HIV), liver disease remains a leading cause of morbidity and mortality for people with HCV, HIV, and especially those living with …

Machine learning models using non-invasive tests & B-mode ultrasound to predict liver-related outcomes in metabolic dysfunction-associated steatotic liver disease

Heather Mary-Kathleen Kosick, Chris McIntosh, Chinmay Bera, Mina Fakhriyehasl et autres

Advanced metabolic-dysfunction-associated steatotic liver disease (MASLD) fibrosis (F3-4) predicts liver-related outcomes. Serum and elastography-based non-invasive tests (NIT) cannot yet reliably predict MASLD outcomes. The role of B-mode ultrasound (US) for outcome prediction is not yet known. We aimed to evaluate machine learning …

ca, us (code pays fourni par la source)

Metabolic factors drive early increase in hepatic steatosis despite improvement in non-invasive fibrosis markers after hepatitis C eradication with direct-acting antivirals

Mohamed Shengir, Wesal Elgretli, Felice Cinque, Agnihotram V. Ramanakumar et autres

BACKGROUND: While direct-acting antivirals (DAAs) achieve high sustained virologic response (SVR) rates in people with hepatitis C virus (HCV), their impact on hepatic steatosis (HS) remains unclear. METHODS: We conducted a retrospective cohort study of 108 HCV patients from McGill University and …

ca, it (code pays fourni par la source)

Validation of FIB-4 for the diagnosis of liver cirrhosis in metabolic dysfunction-associated steatotic liver disease

Chinmay Bera, Nashla Hamdan‐Pérez, Heather Mary-Kathleen Kosick, Mohamed Shengir et autres

American Association for the Study of Liver Diseases practice guidance on metabolic dysfunction-associated steatotic liver disease (MASLD) has recommended using specific cut-off values for the Fibrosis-4 index (FIB-4) to detect cirrhosis. A cut-off of 3.48 is recommended for identifying stage 4 fibrosis …

ca, us (code pays fourni par la source)

High burden of MASLD and metALD in People with HIV: a call for liver fibrosis screening prioritization

Felice Cinque, Jovana Milić, Rita Righetti, Dana Kablawi et autres

ca, it, de (code pays fourni par la source)

Association of MASLD Phenotypes With Liver Fibrosis in Hepatitis C: The Role of Cardiometabolic Risk Factors

Wesal Elgretli, Mohamed Shengir, Shlomo Sasson, Agnihotram V. Ramanakumar et autres

Steatotic liver disease is prevalent among people with hepatitis C virus (HCV). The new definition of metabolic dysfunction-associated steatotic liver disease (MASLD) emphasises the metabolic drivers of steatosis and recognises its frequent coexistence with other chronic liver diseases, including HCV. We aimed …

ca, it (code pays fourni par la source)

Switch to a raltegravir‐based antiretroviral regimen in people with HIV and non‐alcoholic fatty liver disease: A randomized controlled trial

Mohamed Shengir, Bertrand Lebouché, Wesal Elgretli, Sahar Saeed et autres

INTRODUCTION: The effect of antiretroviral therapy (ART), particularly integrase strand transfer inhibitors (INSTIs), on non-alcoholic fatty liver disease (NAFLD) in people with HIV remains unclear. We evaluated the effect of switching non-INSTI backbone antiretroviral medications to raltegravir on NAFLD and metabolic parameters. …

ca (code pays fourni par la source)

Increased Serum Fibroblast Growth Factor 23 Predicts Mortality in People With HIV/HCV Coinfection

Mohamed Shengir, Carine Fillebeen, John Wagner, Agnihotram V. Ramanakumar et autres

BACKGROUND: People with HIV and hepatitis C virus (HCV) coinfection experience excess mortality because of multiple causes. Identification of biomarkers associated with mortality beyond that attributable to liver fibrosis may be relevant for prognostication. Fibroblast growth factor 23 (FGF23), a phosphotropic hormone, …

ca (code pays fourni par la source)

Sa1602 THE UTILITY OF AMAP SCORE IN PREDICTING HEPATOCELLULAR CARCINOMA RISK IN PATIENTS WITH ADVANCED NON-ALCOHOLIC FATTY LIVER DISEASE

Chinmay Bera, Heather Mary-Kathleen Kosick, Mohamed Shengir, Oyedele Adewale Adeyi et autres

Impacts of the COVID-19 pandemic on hepatitis C elimination in Canada: Where do we go from here?

Jawairia Atif, Sasha Tejna Persaud Udhesister, Mohamed N. Abdelnabi, Simmone D’souza et autres

ca, us, gb (code pays fourni par la source)

Development and validation of an ensemble machine learning framework for detection of all-cause advanced hepatic fibrosis: a retrospective cohort study

Soren Sabet Sarvestany, Jeffrey C. Kwong, Amirhossein Azhie, Victor M. Dong et autres

BACKGROUND: Cirrhosis is the result of advanced scarring (or fibrosis) of the liver, and is often diagnosed once decompensation with associated complications has occurred. Current non-invasive tests to detect advanced liver fibrosis have limited performance, with many indeterminate classifications. We aimed to …

ca (code pays fourni par la source)

A220 THE IMPACT OF DIABETES AND AGE ON PERFORMANCE OF NON-INVASIVE SERUM-BASED TESTS FOR PREDICTION OF ADVANCED FIBROSIS IN BIOPSY-PROVEN NAFLD

Heather Mary-Kathleen Kosick, Mohamed Shengir, Oyedele Adewale Adeyi, Giada Sebastiani et autres

Abstract Background Non-alcoholic fatty liver disease (NAFLD) is now a leading cause of end-stage liver disease. Advanced stage F3-4 fibrosis predicts liver-related mortality in NAFLD patients. Simple non-invasive serum-based tests (NIT) for F3-4 are limited by indeterminate scores, necessitating secondary tests or …

ca, us (code pays fourni par la source)